• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    FDA Approves Luye Pharma`s ERZOFRI For Schizophrenia Treatment

    PR NEWSWIRE

    New Data Provide Schizophrenia Insights On Switching To UZEDY

    BUSINESSWIRE

    Teva, Viatris win new chance to challenge J&J schizophrenia drug patent

    REUTERS

    Pharmascience`s Generic Paliperidone Palmitate Receives Approval in the U.S.

    FDA

    Tolmar`s Generic Paliperidone Palmitate Receives Approval in the U.S.

    FDA

    Byannli authorised in Britain for schizophrenia treatment

    PHARMATIMES

    Janssen’s Byannli receives EU approval for maintenance of schizophrenia

    PHARMABIZ

    European Commission approves BYANNLI for management of schizophrenia in adults

    PHARMAFILE

    Janssen Receives Positive CHMP Opinion for BYANNLI®

    BUSINESSWIRE

    Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™

    PRNEWSWIRE

    Teva Pharms`s Generic Paliperidone Palmitate Receives Approval In US

    FDA

    Janssen Submits MKT Authorisation Extension EMA to Paliperidone Palmitate

    BUSINESSWIRE

    Janssen Submits Paliperidone Palmitate 6-Month (PP6M) sNDA to U.S. FDA

    PRNEWSWIRE

    FDA Confirms Paragraph IV Patent Challenge of Invega Trinza 207946 (Paliperidone Palmitate) Extended-release Injectable Suspension 546 mg/1.75 mL

    FDA

    Janssen-Cilag Generic Paliperidone palmitate Receives Approval in Europe

    EMA

    Janssen Signs Contract with Oklahoma Health Care for Long-Acting Injectable

    PR NEWSWIRE

    FDA Confirms Paragraph IV Patent Challenge of Invega Sustenna (Paliperidone Palmitate) Extended-release Injectable Suspension

    FDA

    Alkermes to Initiate New Clinical Study Evaluating ARISTADA® & INVEGA SUSTENNA®

    BUSINESSWIRE

    Janssen Receives CHMP Positive Opinion for Trevicta

    PHARMAASIA

    Janssen launches schizophrenia drug Invega Trinz in US

    PHARMABIZ

    J&J promises new uses for old meds to keep pharma sales flying high

    FIERCE PHARMA

    Janssen`s Invega Trinza (3- Month Paliperidone Palmitate) Approved in US For Schizophrenia

    JANSSEN

    J&J Receives FDA Complete Response Letter for Invega Sustenna Label Change

    DCAT

    Patients Blame Cost for Coverage Delay in England of Gilead Drug

    PHARMALOT

    FDA Grants Priority Review for Three Month Paliperidone Palmitate for the Treatment of Schizophrenia

    PR NEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.